Moving Forward: Shire’s Longer-Lasting Adderall XR, SHP 465

  Update: 2017 finally saw approval for Shire-Takeda’s long-acting mixed-amphetamine salt medication for ADHD.  This gives the company another long-acting amphetamine medication as its Vyvanse patent is set to expire in June 2023. Now called …

Moving Forward: Shire’s Longer-Lasting Adderall XR, SHP 465 Read More »